VEGFA and neoplasm: Using a murine model that simulates the scenario in human patients, we have shown that treatment of the tumor-bearing mice with VEGF aptamer-targeted αGal hapten prevented tumor growth (Fig. 6), and recruited antibodies from 4/4 human sera tested (Fig. 7b) to 5/5 human tumor sections of distinct origin (Fig. 7c).